![Peter Olagunju](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Olagunju
Directeur Général chez
ImmunoSCAPE Pte Ltd.
Profil
Mr. Peter Olagunju is a Chief Executive Officer at ImmunoScape Pte Ltd. and a Chairman at March Biosciences, Inc. Mr. Olagunju was previously employed as a Chief Operating Officer by TCR² Therapeutics, Inc., a Senior Vice President-Technical Operations by FerGene, Inc., a Vice President-Global Patient Operations by bluebird bio, Inc., a Head-Quality by Dendreon Corp., and a Head-Quality by ZymoGenetics, Inc. He received his undergraduate degree from the University of Illinois At Urbana–Champaign and an MBA from Foster School of Business.
Postes actifs de Peter Olagunju
| Sociétés | Poste | Début |
|---|---|---|
ImmunoSCAPE Pte Ltd.
 ImmunoSCAPE Pte Ltd. BiotechnologyHealth Technology Operates as a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T cell therapies | Directeur Général | 23/09/2026 |
Anciens postes connus de Peter Olagunju
| Sociétés | Poste | Fin |
|---|---|---|
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Corporate Officer/Principal | 01/07/2021 |
| GENETIX BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2020 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Corporate Officer/Principal | - |
| DENDREON CORPORATION | Corporate Officer/Principal | - |
| TCR2 THERAPEUTICS INC. | Directeur des opérations | - |
Formation de Peter Olagunju
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
51
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
University of Illinois At Urbana–Champaign
 University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ImmunoSCAPE Pte Ltd.
ImmunoSCAPE Pte Ltd. BiotechnologyHealth Technology Operates as a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T cell therapies | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Health Technology |
Foster School of Business
 Foster School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
